| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfd4c6559bd98afae743866baff20261 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-592
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-592
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-593 |
| filingDate |
2014-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebc1c66dfb856e5d135d8b9480062377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_452f7a003c5ec71c51b3f7b30aedd979
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_342c0b3af88cb66ae1fb793263a587d9 |
| publicationDate |
2014-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014065751-A |
| titleOfInvention |
Treatment of vitamin D deficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 |
| abstract |
Methods and compositions for treating 25-hydroxyvitamin D deficiency and deficiency in a patient are provided. The method of the present invention is selected from the group consisting of 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or a combination of 25-hydroxyvitamin D 2 and 25-hydroxyvitamin D 3 for the patient. Or a method comprising orally administering a delayed sustained release formulation comprising a first ingredient to be administered to a patient, wherein the method comprises 25-hydroxyvitamin D 2 , 25-hydroxyvitamin D 3 , or 25-hydroxyvitamin D 2 and sterile intravenous formulation comprising a first component selected from the group consisting of 25-hydroxyvitamin D 3 comprising administering progressively. [Selection figure] None |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018131423-A |
| priorityDate |
2006-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |